share_log

Avalo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Venrock Healthcare Capital Partners III, L.P.(0.0%),VHCP Co-Investment Holdings III, LLC(0.0%), etc.

Avalo Therapeutics | SC 13G/A：超过5%持股股东披露文件(修正)-Venrock Healthcare Capital Partners III, L.P.(0.0%),VHCP Co-Investment Holdings III, LLC(0.0%)等

SEC announcement ·  02/14 21:18
Moomoo AI 已提取核心信息
A group of entities and individuals, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, have filed an amended Schedule 13G/A with the SEC, indicating they no longer beneficially own more than five percent of Avalo Therapeutics, Inc.'s common stock as of December 31, 2023. The filing, dated February 14, 2024, confirms that each reporting person within the group holds zero shares and has zero percent ownership of the class, signifying a complete divestment from Avalo Therapeutics. The entities and individuals are primarily organized under the laws of Delaware, with Shah and Koh being United States citizens. The filing ensures that the disposition of the shares is not for the purpose of changing or influencing the control of Avalo Therapeutics.
A group of entities and individuals, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, have filed an amended Schedule 13G/A with the SEC, indicating they no longer beneficially own more than five percent of Avalo Therapeutics, Inc.'s common stock as of December 31, 2023. The filing, dated February 14, 2024, confirms that each reporting person within the group holds zero shares and has zero percent ownership of the class, signifying a complete divestment from Avalo Therapeutics. The entities and individuals are primarily organized under the laws of Delaware, with Shah and Koh being United States citizens. The filing ensures that the disposition of the shares is not for the purpose of changing or influencing the control of Avalo Therapeutics.
包括Venrock Healthcare Capital Partners III、L.P.、VHCP Co-Investment Holdings III, LLC、VHCP Management III, LLC、VHCP Management EG, LLC、Nimish Shah和Bong Koh在内的一系列实体和个人已向美国证券交易委员会提交了经修订的附表13G/A，表明他们不再以实益方式拥有Avalo Therapeutics, Inc.5％以上的股份。”截至2023年12月31日的普通股。这份日期为2024年2月14日的文件证实，该集团内每位申报人持有零股份，该集团的所有权为零，这表明已完全从Avalo Therapeutics撤资。这些实体和个人主要根据特拉华州的法律组建，Shah和Koh是美国公民。该文件确保处置股份的目的不是为了改变或影响Avalo Therapeutics的控制权。
包括Venrock Healthcare Capital Partners III、L.P.、VHCP Co-Investment Holdings III, LLC、VHCP Management III, LLC、VHCP Management EG, LLC、Nimish Shah和Bong Koh在内的一系列实体和个人已向美国证券交易委员会提交了经修订的附表13G/A，表明他们不再以实益方式拥有Avalo Therapeutics, Inc.5％以上的股份。”截至2023年12月31日的普通股。这份日期为2024年2月14日的文件证实，该集团内每位申报人持有零股份，该集团的所有权为零，这表明已完全从Avalo Therapeutics撤资。这些实体和个人主要根据特拉华州的法律组建，Shah和Koh是美国公民。该文件确保处置股份的目的不是为了改变或影响Avalo Therapeutics的控制权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息